ArticleCase reports in pediatrics2011
Mesalamine-induced myocarditis and coronary vasculitis in a pediatric ulcerative colitis patient: a case report.
Article in Case reports in pediatrics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Microbiota and inflammatory bowel disease: the dual effect mechanism of polysaccharide therapy.Frontiers in immunology · 2025Review
- A Comprehensive Review of Xanthan Gum-Based Oral Drug Delivery Systems.International journal of molecular sciences · 2024Review
- Myocarditis Related to the Use of Mesalazine.Journal of medical cases · 2023Article
- Review
- Urinary manifestations in African American and Caucasian inflammatory bowel disease patients: a retrospective cohort study.BMC urology · 2022Article
- Analysis of clinical characteristics of mesalazine-induced cardiotoxicity.Frontiers in pharmacology · 2022Article
- Recurrent myocarditis in a patient with active ulcerative colitis: a case report and review of the literature.BMJ open gastroenterology · 2021Review
- Article
- Myocarditis Secondary to Mesalamine-Induced Cardiotoxicity in a Patient with Ulcerative Colitis.Case reports in medicine · 2018Article
- Five-aminosalicylic Acid: an update for the reappraisal of an old drug.Gastroenterology research and practice · 2015Review
- Mesalazine-Induced Myopericarditis in a Patient with a Recent Diagnosis of Crohn's Disease: Apropos of a Case.Case reports in cardiology · 2015Article
- Myopericarditis in a patient with ulcerative colitis treated with mesalamine-Case report and review of the literature.Journal of cardiology cases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesalamine-containing products are often a first-line treatment for ulcerative colitis. Severe adverse reactions to these products, including cardiovascular toxicity, are rarely seen in pediatric patients. We present a case of a 16-year-old boy with ulcerative colitis treated with Asacol, a mesalamine-containing product, who developed sudden onset chest pain after four weeks on therapy. Serial electrocardiograms showed nonspecific ST segment changes, an echocardiogram showed mildly decreased left ventricular systolic function with mild to moderate left ventricular dilation and coronary ectasia, and his troponins were elevated. Following Asacol discontinuation, his chest pain resolved, troponins were trending towards normal, left ventricular systolic function normalized, and coronary ectasia improved within 24 hours suggesting an Asacol-associated severe drug reaction. Mesalamine-induced cardiovascular toxicity, although rare, may represent a life-threatening disorder. Therefore, every patient presenting with acute chest pain should receive a workup to rule out this rare drug-induced disorder.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.